Recurrent venous thrombosis during direct oral anticoagulant therapy in a patient with protein S deficiency.
VTE
apixavan
congenital thrombophilia
Journal
The journal of medical investigation : JMI
ISSN: 1349-6867
Titre abrégé: J Med Invest
Pays: Japan
ID NLM: 9716841
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
9
5
2019
pubmed:
9
5
2019
medline:
18
12
2019
Statut:
ppublish
Résumé
Protein S (PS) deficiency is an inherited thrombophilia associated with an increased risk of venous thromboembolism (VTE). In Japan, unfractionated heparin followed by warfarin has been historically applied for the treatment of VTE. Recent evidence showed that direct oral anticoagulants (DOACs) were non-inferior to standard therapy with warfarin, with significantly less bleeding in patients with VTE. However, it is unknown whether DOACs are effective for the treatment of VTE in patients with thrombophilia, including protein S deficiency, due to lack of evidence. Here, we report a case of recurrent venous thrombosis during edoxaban therapy in a patient with protein S deficiency, which was successfully treated using high-dose apixaban therapy. J.Med. Invest. 66 : 182-184, February, 2019.
Substances chimiques
Anticoagulants
0
Pyrazoles
0
Pyridines
0
Pyridones
0
Thiazoles
0
apixaban
3Z9Y7UWC1J
edoxaban
NDU3J18APO
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM